UCB:EBR
UCB SA
204,60 €
arrow_downward
-0,68%(-1,40) 1D
16 հոկ, 17:37:21 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for UCB...
Open
204,50 €
High
205,10 €
Low
201,30 €
Mkt. cap
39,39 մլրդ
Avg. vol.
255,01 հզր
Volume
324,45 հզր
Dividend
0,50%
Quarterly dividend
0,25 €
Ex-dividend date
04 մյս, 2026 թ.
P/E ratio
18,09
52-wk high
289,50 €
52-wk low
197,45 €
EPS
11,31 €
Shares outstanding
194,51 մլն
No. of employees
9 հզր
Open
204,50 €
High
205,10 €
Low
201,30 €
Mkt. cap
39,39 մլրդ
Avg. vol.
255,01 հզր
Volume
324,45 հզր
Dividend
0,50%
Quarterly dividend
0,25 €
Ex-dividend date
04 մյս, 2026 թ.
P/E ratio
18,09
52-wk high
289,50 €
52-wk low
197,45 €
EPS
11,31 €
Shares outstanding
194,51 մլն
No. of employees
9 հզր
News stories
From web sources and news partners
Simply Wall Street
·
5 րոպե առաջ
Adeia Stock Gets A Charter License Renewal
BigGo Finance
·
12 րոպե առաջ
South Korea's FSS Chief Says Solidigm's Nasdaq Listing Would Constitute Duplicate Listing, Hints at Conveying Concerns to SK Hynix
Bloomberg.com
·
6 ժամ առաջ
US Stock Futures Rise Ahead of Busy Earnings Week: Markets Wrap
Profile
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
About UCB SA